1. |
- Berggren, S, et al.
(författare)
-
Regional transport and metabolism of roivacaine and its CYP3A4 metabolite PPX in human intestine
- 2003
-
Ingår i: Journal of Pharmacy and Pharmacology. - : Oxford University Press (OUP). - 0022-3573 .- 2042-7158. ; 55:7, s. 963-972
-
Tidskriftsartikel (refereegranskat)abstract
- The major aim of this study was to investigate the CYP3A4 metabolism and polarized transport of ropivacaine and its metabolite 2',6'-pipecoloxylidide (PPX) in tissue specimens from the human small and large intestine. Ropivacaine has been shown to be effective in the treatment of ulcerative colitis in human colon. This study was conducted using a modified Ussing-chamber technique with specimens from jejunum, ileum and colon collected from 11 patients. The local kinetics of ropivacaine and PPX were assessed from their concentration-time profiles in mucosal and serosal compartments. The permeability (P-app) in the absorptive direction for both ropivacaine and PPX increased regionally in the order jejunum
|
|
2. |
|
|
3. |
- Ekelund, Mats, et al.
(författare)
-
Pharmaceutical pricing in a regulated market
- 2003
-
Ingår i: Review of Economics and Statistics. - : Massachusetts Institute of Technology Press (MIT Press): Economics Titles. - 1530-9142 .- 0034-6535. ; 85:2, s. 298-306
-
Tidskriftsartikel (refereegranskat)abstract
- We compare how new pharmaceuticals are priced in the price-regulated Swedish market with how they are priced in the U.S. market, as studied by Lu and Comanor (1998). We collect a data set consisting of all new chemical entities (NCEs) launched in Sweden between 1987 and 1997, and test the same models as Lu and Comanor. In line with their results, we find that introductory prices depend on the degree of therapeutic innovation. Contrary to the results from the U.S. market, Swedish real prices for NCEs fall substantially over time for all classes of therapeutic innovation. Also contrary to the findings of Lu and Comanor, we find no effect of the presence of branded substitutes on either introduction prices or price dynamics. Our results indicate that the price regulation discourages price competition between brandname drugs.
|
|
4. |
|
|
5. |
|
|